Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acn
Related stories
AAON Expands Credit Facility to Up to $1.2 Billion
AAON said it refinanced and expanded its credit facility to up to $1.2 billion.
M impact | EQUITY | Nov 12, 2026, 03:11 PM UTC
Hyperliquid Nvidia Perpetual Futures Reach Nearly $2 Billion in 24-Hour Volume
The Nvidia-linked contract ranked second on Hyperliquid, behind Bitcoin perpetual futures.
M impact | EQUITY | Nov 12, 2026, 03:10 PM UTC
Page Industries Shares Plunge 13% as Higher Raw-Material Costs Hit Q2 Profitability
Page Industries shares fell 13% to Rs. 31,850, their lowest level since April, as investors reacted to second-quarter profitability pressure from higher raw-material costs.
M impact | EQUITY | Nov 12, 2026, 03:09 PM UTC
Maersk Opens Montevideo Logistics Facility With Investment Above USD 20 Million
Maersk opened a logistics facility in Montevideo, investing more than USD 20 million.
M impact | EQUITY | Nov 12, 2026, 03:07 PM UTC
US Neocloud Stocks Fall Up to 16% After Huang Resigns as Nvidia CEO
Nebius led losses in early US trading as investors assessed the implications of Jensen Huang's resignation from Nvidia.
M impact | EQUITY | Nov 12, 2026, 03:06 PM UTC
Southern Company Announces $1.75 Billion Mandatory Convertible
Southern Company announced a $1.75 billion mandatory convertible. Its shares edged down.
M impact | EQUITY | Nov 12, 2026, 03:05 PM UTC